These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36482605)

  • 1. Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
    Li D; Yao L; Xu L; Li W; Che Y
    Medicine (Baltimore); 2022 Dec; 101(48):e32164. PubMed ID: 36482605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs.
    Li D; Li W; Xu L; Che Y; Cheng C
    Medicine (Baltimore); 2022 Dec; 101(50):e32169. PubMed ID: 36550917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
    PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
    J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
    Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis.
    Liu Y; Zhang Y; Feng G; Niu Q; Xu S; Yan Y; Li S; Jing M
    Exp Ther Med; 2017 Nov; 14(5):4017-4032. PubMed ID: 29104622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
    An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
    Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
    Biaoxue R; Hua L; Wenlong G; Shuanying Y
    Oncotarget; 2016 Dec; 7(52):86902-86913. PubMed ID: 27893423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.
    Lu S; Zhou J; Jian H; Wu L; Cheng Y; Fan Y; Fang J; Chen G; Zhang Z; Lv D; Jiang L; Wu R; Jin X; Zhang X; Zhang J; Xie C; Sun G; Huang D; Cui J; Guo R; Han Z; Chen Z; Liang J; Zhuang W; Hu X; Zang A; Zhang Y; Cang S; Lan Y; Chen X; Liu L; Li X; Chen J; Ma R; Guo Y; Sun P; Tian P; Pan Y; Liu Z; Cao P; Ding L; Wang Y; Yuan X; Wu P
    Lancet Respir Med; 2023 Oct; 11(10):905-915. PubMed ID: 37244266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
    Li D; Li M; Li H; Shi P; Chen M; Yang T
    Dis Markers; 2023; 2023():5272125. PubMed ID: 37077340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
    Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
    Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
    Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.
    Wang BC; Zhang WX; Kuang BH; Lin GH
    PLoS One; 2022; 17(10):e0275919. PubMed ID: 36215289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
    Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
    Cancer Med; 2020 Jan; 9(1):12-18. PubMed ID: 31692291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
    Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.
    Zhang L; Wang L; Wang J; Chen J; Meng Z; Liu Z; Jiang X; Wang X; Huang C; Chen P; Liang Y; Jiang R; Wang J; Zhong D; Shang Y; Zhang Y; Zhang C; Huang D
    Mol Cancer; 2023 Aug; 22(1):124. PubMed ID: 37543587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.